person · Reporting owner

Mead Dana G Jr.

Disclosed activity across 5 companies

Tapewire entity: 40169
SEC CIK: 0001222358

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inspire Medical Systems, Inc.INSP · Entity 1186	Director	April 30, 2026	May 04, 2026
Intersect ENT, Inc.XENT · Entity 127294	Director	May 13, 2022	May 16, 2022
Mobia Medical, Inc.MOBI · Entity 5669	Director	May 07, 2026	May 12, 2026
Pulmonx CorpLUNG · Entity 2359	Director	June 05, 2026	June 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inspire Medical Systems, Inc.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,213	Reported balance After 2026-04-30 transaction · row 1 1 source row Row 1 · 2026-04-30 · Grant · Acquired 3,562 · Balance 26,213 F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Intersect ENT, Inc.

Report date May 13, 2022 · Filed May 16, 2022

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2022-05-13 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-05-13 · Other · Disposed 20,890 · Balance 3,239 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Row 2 · 2022-05-13 · Other · Disposed 3,239 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2029-06-03	Direct	Reported balance After 2022-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-13 · Other · Disposed 5,172 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.53 · Expires 2024-09-04	Direct	Reported balance After 2022-05-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.50 · Expires 2031-06-02	Direct	Reported balance After 2022-05-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-13 · Other · Disposed 5,734 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.79 · Expires 2026-06-01	Direct	Reported balance After 2022-05-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.84 · Expires 2030-06-03	Direct	Reported balance After 2022-05-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-05-13 · Other · Disposed 9,666 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.05 · Expires 2028-06-04	Direct	Reported balance After 2022-05-13 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-05-13 · Other · Disposed 3,473 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2025-06-03	Direct	Reported balance After 2022-05-13 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31	Direct	Reported balance After 2022-05-13 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-05-13 · Other · Disposed 6,035 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].

F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

Mobia Medical, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,000	Reported balance After 2026-05-11 transaction · row 1 1 source row Row 1 · 2026-05-11 · Purchase · Acquired 7,000 · Balance 7,000
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-05-07	Direct	31,520	Reported balance After 2026-05-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-07 · Grant · Acquired 31,520 · Balance 31,520 F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.

Pulmonx Corp

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	139,714	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 139,714 F1: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,076	Reported balance Holding disclosure · report date 2026-06-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,076 F2: The shares are held directly by the Dana G. Mead, Jr. And D'Arcy Gage Mead, or Their Successors, as Trustees of The Mead Family Trust Created Uta Dated August 4, 1998, as Amended.

Filing footnotes · ownership attribution and instrument terms

F1: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made.

F2: The shares are held directly by the Dana G. Mead, Jr. And D'Arcy Gage Mead, or Their Successors, as Trustees of The Mead Family Trust Created Uta Dated August 4, 1998, as Amended.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Inari Medical, Inc.

Report date February 19, 2025 · Filed February 20, 2025

Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-19 transaction · row 1 1 source row Row 1 · 2025-02-19 · Other · Disposed 11,148 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 9, 2026 21:49 UTC	Pulmonx Corp LUNG · Entity 2359	GrantCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001222358-26-000002 · form4-06092026_090640.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,714 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document
May 11, 2026 Filed May 12, 2026 01:36 UTC	Mobia Medical, Inc. MOBI · Entity 5669	PurchaseCommon Stock	7,000	$15.00	$105,000.00	Disclosure SEC source: 0001628280-26-033807 · wk-form4_1778549790.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Read SEC document
May 07, 2026 Filed May 12, 2026 01:36 UTC	Mobia Medical, Inc. MOBI · Entity 5669	GrantStock Option · Derivative	31,520	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0001628280-26-033807 · wk-form4_1778549790.xml · derivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,520 Underlying: Common Stock · 31,520 shares Expires 2036-05-07 F1 · derivative.exercise_date: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date. Read SEC document
April 30, 2026 Filed May 4, 2026 22:27 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	3,562	$0.00	$0.00	Disclosure SEC source: 0001104659-26-055065 · tm2613528-7_4seq1.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,213 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document
June 02, 2025 Filed Jun 4, 2025 21:58 UTC	Pulmonx Corp LUNG · Entity 2359	GrantCommon Stock	37,153	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015636 · form4-06042025_090625.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,714 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 2, 2025, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document
May 01, 2025 Filed May 5, 2025 23:25 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	1,266	$0.00	$0.00	Disclosure SEC source: 0001104659-25-044667 · tm2514079-2_4seq1.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,651 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document
February 19, 2025 Filed Feb 20, 2025 01:05 UTC	Inari Medical, Inc. NARI · Entity 83035	OtherCommon Stock	11,148	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-005740 · form4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2 · shares: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document
June 03, 2024 Filed Jun 5, 2024 21:51 UTC	Pulmonx Corp LUNG · Entity 2359	GrantCommon Stock	15,216	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015625 · form4-06052024_090656.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,561 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 3, 2024, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document
May 02, 2024 Filed May 6, 2024 22:16 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	716	$0.00	$0.00	Disclosure SEC source: 0001104659-24-057570 · tm2413647-5_4seq1.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,385 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document
April 24, 2024 Filed Apr 26, 2024 20:52 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	4,126	$42.41	$174,983.66	Disclosure SEC source: 0001127602-24-013472 · form4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,148 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document
April 24, 2024 Filed May 31, 2024 20:49 UTC Amendment	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	4,126	$42.41	$174,983.66	Disclosure SEC source: 0001127602-24-017127 · form4a.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,148 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document
June 01, 2023 Filed Jun 2, 2023 22:24 UTC	Pulmonx Corp LUNG · Entity 2359	GrantCommon Stock	12,620	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033981 · doc4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,345 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 1, 2023, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document
May 18, 2023 Filed May 19, 2023 22:14 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	2,412	$0.00	$0.00	Disclosure SEC source: 0001127602-23-016360 · form4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,022 F1 · shares: Represents RSUs granted on May 18, 2023, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2024 annual meeting. Read SEC document
April 27, 2023 Filed May 1, 2023 23:53 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	669	$0.00	$0.00	Disclosure SEC source: 0001104659-23-054655 · tm2314266-10_4seq1.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,669 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document
June 01, 2022 Filed Jun 3, 2022 22:14 UTC	Pulmonx Corp LUNG · Entity 2359	GrantCommon Stock	5,600	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034321 · doc4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,725 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 1, 2022, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document
May 26, 2022 Filed May 27, 2022 20:35 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	2,420	$0.00	$0.00	Disclosure SEC source: 0001127602-22-015873 · form4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 F1 · shares: Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	6,035	$28.25 Strike: $26.05	$170,488.75	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 10 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,035 shares Expires 2027-05-31 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	12,500	$28.25 Strike: $27.45	$353,125.00	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 9 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2025-06-03 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	3,473	$28.25 Strike: $42.05	$98,112.25	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 8 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,473 shares Expires 2028-06-04 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	9,666	$28.25 Strike: $11.84	$273,064.50	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 7 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,666 shares Expires 2030-06-03 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	12,500	$28.25 Strike: $13.79	$353,125.00	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 6 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2026-06-01 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	5,734	$28.25 Strike: $16.50	$161,985.50	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 5 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires 2031-06-02 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	12,500	$28.25 Strike: $16.53	$353,125.00	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 4 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2024-09-04 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	5,172	$28.25 Strike: $23.02	$146,109.00	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · derivative · entry 3 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,172 shares Expires 2029-06-03 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherCommon Stock	3,239	$28.25	$91,501.75	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · nonDerivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherCommon Stock	20,890	$28.25	$590,142.50	Disclosure SEC source: 0001562180-22-004067 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,239 F1 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Read SEC document
April 28, 2022 Filed May 11, 2022 00:44 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantStock Option (right to buy) · Derivative	1,243	$0.00 Strike: $211.29	$0.00	Disclosure SEC source: 0001104659-22-058413 · tm2215111d1_4seq1.xml · derivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243 Underlying: Common Stock · 1,243 shares Expires 2032-04-28 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 28, 2023, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
October 01, 2021 Filed Oct 5, 2021 21:59 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	2,190	$0.00	$0.00	Disclosure SEC source: 0001562180-21-006321 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,190 F1 · shares: Represents Restricted Stock Units ("RSUs") that vests 1/3 on each of the first, second and third anniversary of the grant date. Read SEC document
June 03, 2021 Filed Jun 7, 2021 21:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	5,734	$0.00 Strike: $16.50	$0.00	Disclosure SEC source: 0001562180-21-004116 · primarydocument.xml · derivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires 2031-06-02 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 3, 2021. Read SEC document
June 03, 2021 Filed Jun 7, 2021 21:34 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	3,239	$0.00	$0.00	Disclosure SEC source: 0001562180-21-004116 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,129 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 3, 2022. F2 · balance_after: Includes 3,239 restricted stock units. Read SEC document
June 01, 2021 Filed Jun 12, 2021 00:18 UTC	Pulmonx Corp LUNG · Entity 2359	GrantCommon Stock	2,810	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040072 · doc4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,125 F1 · shares: Represents grant of Restricted Stock Units payable solely in common stock of the Issuer that will vest on the one-year anniversary of the date of grant of June 1, 2021. Read SEC document
April 29, 2021 Filed May 3, 2021 21:10 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantStock Option (right to buy) · Derivative	1,175	$0.00 Strike: $240.68	$0.00	Disclosure SEC source: 0001104659-21-060305 · tm2114992-2_4seq1.xml · derivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175 Underlying: Common Stock · 1,175 shares Expires 2031-04-29 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 29, 2022, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	ConversionSeries E-1 Preferred Stock · Derivative	87,475	$0.00	$0.00	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · derivative · entry 7 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 102,725 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	ConversionSeries D-1 Preferred Stock · Derivative	168,223	$0.00	$0.00	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · derivative · entry 6 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 168,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 102,725 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	ConversionSeries C-1 Preferred Stock · Derivative	1,268,411	$0.00	$0.00	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · derivative · entry 5 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,268,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 102,725 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	PurchaseCommon Stock	26,315	$19.00	$499,985.00	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · nonDerivative · entry 4 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,315 Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	ConversionCommon Stock	87,475	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · nonDerivative · entry 3 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,524,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 102,725 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	ConversionCommon Stock	168,223	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · nonDerivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,436,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 102,725 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
October 05, 2020 Filed Oct 5, 2020 20:16 UTC	Pulmonx Corp LUNG · Entity 2359	ConversionCommon Stock	1,268,411	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-014283 · wf-form4_160192892933103.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,268,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are directly held by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 102,725 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document
September 30, 2020 Filed Oct 2, 2020 20:13 UTC	Pulmonx Corp LUNG · Entity 2359	GrantEmployee Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001628280-20-014200 · wf-form4_160166957516690.xml · derivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in 36 equal consecutive monthly installments commencing on September 30, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:53 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	9,666	$0.00 Strike: $11.84	$0.00	Disclosure SEC source: 0001562180-20-004320 · primarydocument.xml · derivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,666 Underlying: Common Stock · 9,666 shares Expires 2030-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020. Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:53 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	5,011	$0.00	$0.00	Disclosure SEC source: 0001562180-20-004320 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,890 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021. F2 · balance_after: Includes 5,011 restricted stock units. Read SEC document
April 30, 2020 Filed May 5, 2020 00:39 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantStock Option (right to buy) · Derivative	3,501	$0.00 Strike: $71.66	$0.00	Disclosure SEC source: 0001104659-20-056422 · a4.xml · derivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,501 Underlying: Common Stock · 3,501 shares Expires 2030-04-30 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 30, 2021, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:12 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	5,172	$0.00 Strike: $23.02	$0.00	Disclosure SEC source: 0001562180-19-003401 · primarydocument.xml · derivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Underlying: Common Stock · 5,172 shares Expires 2029-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2019. Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:12 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	2,312	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003401 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,879 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2020. F2 · balance_after: Includes 2,312 restricted stock units. Read SEC document
May 02, 2019 Filed May 6, 2019 21:58 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantStock Option (right to buy) · Derivative	4,569	$0.00 Strike: $49.96	$0.00	Disclosure SEC source: 0001104659-19-027216 · a4.xml · derivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,569 Underlying: Common Stock · 4,569 shares Expires 2029-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2020, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
August 06, 2018 Filed Aug 17, 2018 19:04 UTC	Intersect ENT, Inc. XENT · Entity 127294	PurchaseCommon Stock	3,811	$26.22	$99,942.33	Disclosure SEC source: 0001562180-18-003703 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,567 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.075 to $26.30, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares purchase at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,514 Restricted Stock Units. Read SEC document
June 05, 2018 Filed Jun 7, 2018 17:18 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Options (Right to buy) · Derivative	3,473	$0.00 Strike: $42.05	$0.00	Disclosure SEC source: 0001562180-18-002915 · primarydocument.xml · derivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Underlying: Common Stock · 3,473 shares Expires 2028-06-04 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018. Read SEC document
June 05, 2018 Filed Jun 7, 2018 17:18 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	1,514	$0.00	$0.00	Disclosure SEC source: 0001562180-18-002915 · primarydocument.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,756 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 5, 2019. F2 · balance_after: Includes 1,514 RSUs. Read SEC document
May 07, 2018 Filed May 10, 2018 01:16 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	PurchaseCommon Stock	20,000	$16.00	$320,000.00	Disclosure SEC source: 0001104659-18-031862 · a4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.